Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer imaging agent. Illuccix claims to be the first prostate-specific membrane ...
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ...
It’s a brave call given the recent market sell-off, but the ASX’s ‘milestone’ moment represents a structural change.
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health ...
Brazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix. ... Read ...
HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHTtm ? now ...
Great-West Lifeco (GWO) has released an update for its Supplemental Information Package (SIP) for 2025 for analysts and ...
Melbourne-based biotech Telix Pharmaceuticals has announced that its prostate cancer diagnostic agent Illuccix has been ...
Join us at the 4th Targeted Radiopharmaceuticals Summit US, returning to San Diego this July, as the largest end-to-end, ...
Elsewhere, Macquarie upgraded supermarket giant Woolworths, and Goldman Sachs downgraded drinks retailer Endeavour Group, ...